- Types of Eczema
- Eczema in Children
- Living Well
- Eczema Products
- Get Involved
Understanding the genetic makeup of people with atopic dermatitis allows scientists to create highly targeted treatments and, potentially, a cure.
Following on the heels of Dupixent (dupilumab)—the first-ever biologic drug for atopic dermatitis (the most common type of eczema), approved by the U.S. Food and Drug Administration (FDA) on March 28—a second biologic may soon be on the way.
Many studies have looked at how teasing and bullying based on appearance affects people physically and mentally.
From dust mites to pet dander, we walk you through the common triggers for asthma and allergic rhinitis and show you how to manage symptoms.
New research reveals a type of yeast found in infants’ stomachs may be strong predictor of childhood asthma.
Bust out that yoga mat because researchers are getting closer to understanding the benefits of stress reduction for inflammatory skin diseases.
The U.S. Food and Drug Administration approved Dupixent (dupilumab), the first biologic medication for adults with moderate to severe atopic dermatitis (AD).
Our skin is covered in a web of billions of tiny organisms including bacteria, viruses and fungi. This web is called the skin microbiome and when healthy, helps our bodies function properly inside and out. Researchers have long known that people with atopic dermatitis (AD) have different skin biology than those who do not have […]
Atopic dermatitis is a hot field of study. Here’s some highlights on eczema research and care from this year’s AAD meeting.
To find out more about why and how pain and sleep problems affect people with atopic dermatitis, the National Eczema Association funded three studies in these areas as part of its 2017 Research Grant Program.